Research Article
Predictive Value of Monocyte Chemoattractant Protein-1 in the Development of Diastolic Dysfunction in Patients with Psoriatic Arthritis
Table 2
Clinical and laboratory characteristics of PsA patients classified into groups with respect to the cut-off MCP-1 concentration (347.6 pg/mL).
| | Patients with serum MCP-1 | value | ≤347.6 pg/mL () Median 25th; 75th percentiles | >347.6 pg/mL () Median 25th; 75th percentiles |
| Clinical characteristics and laboratory parameters | | | | BASDAI | 3.1 (1.05; 3.94) | 4 (2.7; 4.95) | 0.236a | BASFI | 1.75 (1.1; 2.8) | 2 (1.35; 5.6) | 0.19a | DAPSA | 10.6 (8.3; 18.5) | 18.45 (11.77; 32.35) | 0.0000a | BSA (%) | 0.25 (0; 1) | 0 (0; 2) | 0.572a | BMI (kg/m2) | 26.9 (25.65; 29.9) | 30.3 (27.15; 33.8) | 0.082a | Diastolic pressure (mmHg) | 85 (77.25; 92.75) | 89.5 (80; 100) | 0.1a | Systolic pressure (mmHg) | 129.5 (102; 180) | 150 (128.75; 159.25) | 0.01a | CRP (mg/L) | 1.2 (0.8; 2.8) | 1.65 (0.95; 9.1) | 0.249a | Glucose (mmol/L) | 5.2 (4.9; 5.65) | 5.8 (5.3; 6.5) | 0.011a | LDL-cholesterol (mmol/L) | 3.7 (3; 4.1) | 4 (3.57; 5.17) | 0.012a | NT-pro-BNP (pmol/L) | 60 (35; 136) | 57 (42; 62.25) | 0.803a | MCP-1 (pg/L) | 267.7 (214.2; 299.2) | 404.1 (391; 422.9) | 0.00063a | Age (year) | 61 (54; 64) | 62 (55.75; 67.25) | 0.478a | Comorbidities and current therapy () | | | | Type II diabetes | 4 | 3 | 0.503b | Arterial hypertension | 21 | 14 | 0.115b | Cigarette smoking | 7 | 6 | 0.210b | sDMARD | 13 | 7 | 0.705b | TNF inhibitors | 13 | 10 | 0.129b | NSAR | 17 | 3 | 0.051b | ACE inhibitors | 8 | 7 | 0.155b | Beta blockers | 11 | 9 | 0.123b |
|
|
MCP-1: Monocyte Chemoattractant Protein-1; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; DAPSA: Disease Activity in Psoriatic Arthritis; BSA: body surface area; BMI: body mass index; NYHA: New York Heart Association Classification; LDL: low-density lipoprotein; NT-pro-BNP: N-terminal probrain natriuretic peptide; sDMARD: synthetic disease-modifying antirheumatic drugs; TNF: tumor necrosis factor; NSAR: nonsteroid antirheumatics; ACE: angiotensin-converting enzyme. Levels of statistical significance are indicated as values in aMann–Whitney test; bChi-squared test. |